The North American Menopause Society (NAMS) has issued its updated 2017 position statement that contains guidelines for hormone therapy use. The statement includes updated information and new findings since the last issue in 2012. Among the conclusions and new or expanded areas covered in the statement:
- Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause.
- The risks of HT differ for different women and treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation for the benefits and risk of HT continuation.
- For women aged <60 years or who are within 10 years of menopause onset, the benefit-risk ratio appears favorable for HT treatment.
- The risk of heart disease is greater in women who start HT >10 years after menopause onset or after age 60 years.
- Vaginal estrogen or other nonestrogen therapies may be used at any age for prevention or treatment of the genitourinary syndrome or menopause.
Pinkerton JV, for the NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. [Published online ahead of print June 20, 2017]. Menopause. doi:10.1097/GME.0000000000000921.
This Week's Must Reads
Must Reads in Clinical Guidelines
ACOG: Chronic Hypertension in Pregnancy, Obstet Gynecol; ePub 2019 Jan; Vidaeff, et al
ACOG Guidelines: Pregestational Diabetes Mellitus, Obstet Gynecol; ePub 2018 Dec; ACOG, et al
Management of Early Pregnancy Loss, Obstet Gynecol; ePub 2018 Nov; ACOG
Prophylactic Antibiotic Use in Labor & Delivery, Obstet Gynecol; 2018 Sep; Coleman, et al
USPSTF on Screening for Cervical Cancer, JAMA; 2018 Aug 21; US Preventive Services Task Force